Pediatric Dermatology

Update on Pediatric Psoriasis, Part 2: Therapeutic Management

Pediatric psoriasis is an autoimmune diathesis with a complex immunologic basis. It is associated with extensive psychological morbidity and should be treated rapidly and effectively to limit psychologic effects on children. The most common trigger in childhood is upper respiratory tract infection. Once disease has occurred, treatment is based on severity and presence of joint involvement. Topical therapies include corticosteroids and calcipotriene. UV light, systemic retinoids, and cyclosporine remit cutaneous psoriatic lesions. Methotrexate sodium and etanercept benefit both skin and joint manifestations of psoriasis. Concern for psychological symptoms and psychological growth is needed in treating pediatric patients with psoriasis vulgaris.


 

Recommended Reading

Generic Biologics' Safety Questioned as Approval Process Stalls
MDedge Dermatology
Vitamin D - Myths or Truths?
MDedge Dermatology
Adalimumab Found Safe for Psoriatic Diseases
MDedge Dermatology
Cyclosporine Often Best Option for Pediatric Pustular Psoriasis Flare
MDedge Dermatology
Bosentan Reduced Occurrence of Digital Ulcers in Systemic Sclerosis
MDedge Dermatology
Focus on the Psychosocial Impacts of Psoriasis in Women
MDedge Dermatology
Dressing Up Psoriasis
MDedge Dermatology
TNF Antagonists in Rheumatic Patients Linked to Increased Hospitalization for Varicella Zoster
MDedge Dermatology
Improvement in Psoriasis During Rituximab Therapy for Mixed Cryoglobulinemia Type II
MDedge Dermatology
Unusual Case of Pemphigus Vulgaris Mimicking Localized Pustular Psoriasis of the Hands and Feet
MDedge Dermatology